Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX019 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PRX019, single dose | EXPERIMENTAL | Specified dose on specified days |
| PRX019, multiple dose | EXPERIMENTAL | Specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| PRX019 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period * Participant is willing and able to adhere to the study visit schedule a...
PRX019 is an investigational small molecule being developed by Prothena Corporation plc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease or condition it is intended to treat has not been publicly disclosed.
PRX019 is being developed by Prothena Corporation plc, which trades on the Nasdaq under the ticker symbol PRTA. Prothena is the sponsor of the clinical program for this investigational small molecule.
PRX019 is in Phase 1 clinical development. Its single reported trial, a Phase 1 study in healthy adult volunteers, has been completed. PRX019 is investigational and has not been approved by the FDA for any indication.
PRX019 has been evaluated in one clinical trial, NCT06699680, titled Phase 1 Study of PRX019 in Healthy Adult Volunteers. The trial enrolled 50 participants in the United States, was randomized, double-blind, and controlled, and its status is completed.
The therapeutic use of PRX019 has not been disclosed. It is an investigational small molecule that has completed a Phase 1 study in healthy adult volunteers, and no patient indication has been publicly announced for the program.
The completed Phase 1 study of PRX019, NCT06699680, enrolled healthy adult volunteers aged 18 years and older of any sex in the United States. It was a randomized, double-blind, controlled study with 50 participants.